Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Carla M L van Herpen
  • Ulrik Lassen
  • Ingrid M E Desar
  • Kathryn H Brown
  • Marcelo Marotti
  • Maja J A de Jonge
Vis graf over relationer
Vascular endothelial growth factor (VEGF) signalling plays a key role in tumour angiogenesis. Cediranib (AZD2171) is a small-molecule VEGF signalling inhibitor with potent activity against all three VEGF receptors. In this phase I, open-label, parallel-group study, adults with advanced solid tumours received a single 45 mg dose of cediranib, followed by 30 mg continuous once-daily oral dosing for 21 days after a 7-day washout period (clinicaltrials.gov identifier NCT00621725). The primary objective was to compare the single-dose pharmacokinetics (PK) of cediranib in patients with different levels of hepatic impairment classified according to the bilirubin level. Safety, tolerability, multiple-dose PK and PK stratified according to the Child-Pugh criteria were also assessed. Thirty patients received cediranib: 18 with normal-mild hepatic impairment and 12 with moderate hepatic impairment. Single-dose PK parameters were similar between the group with normal-mild hepatic impairment and the group with moderate hepatic impairment [ratio of geometric least square means: area under the curve (AUC) 1.12, 90% confidence interval (CI) 0.77-1.61; Cmax 0.95, 90% CI 0.69-1.31]. Hepatic impairment did not influence PK results in multiple dosing. After continuous once-daily dosing, the geometric least square means ratio was 0.72 (90% CI 0.51-1.03) for AUCSS and 0.67 (90% CI 0.47-0.94) for CSS,max. Similar results were obtained when patients were classified for hepatic impairment according to the Child-Pugh criteria. There was no clear difference in the incidence or the severity of adverse events between hepatic impairment groups. Moderate hepatic impairment does not appear to affect the PK profile or the tolerability of cediranib. Dose adjustments are not necessary in this patient population.
OriginalsprogEngelsk
TidsskriftAnti-Cancer Drugs
Vol/bind24
Udgave nummer2
Sider (fra-til)204-11
Antal sider8
ISSN0959-4973
DOI
StatusUdgivet - 2013

ID: 36614198